The US Onychomycosis Market: Size, Trends & Forecasts (2021-2025 Edition)

Table of Contents

1. Executive Summary

2. Introduction
2.1 Onychomycosis: An Overview
2.1.1 Signs and Symptoms
2.1.2 Causes of Onychomycosis
2.2 Types of Onychomycosis
2.3 Treatment for Onychomycosis

3. Global Market Analysis
3.1 Global Nail Care Market: An Analysis
3.1.1 Global Nail Care Market by Value
3.1.2 Global Nail Care Market by Segment (Onychomycosis (Antifungal Medications and Non Pharmacological Products) and Other Nail Care Products)
3.2 Global Onychomycosis Market: An Analysis
3.2.1 Global Onychomycosis Market by Value
3.2.2 Global Onychomycosis Market by Segment (Kerydin, Jublia and other non pharmacolgic treatments)
3.3 Global Onychomycosis Market: Segment Analysis
3.3.1 Global Kerydin Drugs Market by Value
3.3.2 Global Jublia Drugs Market by Value
3.4 Global Onychomycosis Market: Pipeline Drugs Analysis
3.4.1 Phase II Drugs (Onychomycosis) Pipeline Forecast
3.4.2 Phase III Drugs (Onychomycosis) Pipeline Forecast
3.5 Onychomycosis Market: New Drugs Overview
3.6 Global Onychomycosis Market: Country Analysis
3.6.1 Global Onychomycosis Market by Countries (The US and ROW)

4. The US Market Analysis
4.1 The US Nail Care Market: An Analysis
4.1.1 The US Nail Care Market by Value
4.1.2 The US Nail Care Market by Segments Segment (Onychomycosis (Antifungal Medications and Non Pharmacological Products) and Other Nail Care Products)
4.2 The US Onychomycosis Market: An Analysis
4.2.1 The US Onychomycosis Market by Value
4.3 The US Onychomycosis Market: Type of Treatment Analysis
4.3.1 The US Onychomycosis Market by Type of Treatment (Pharmacological and Non Pharmacological)
4.3.2 The US Pharmacological Onychomycosis Market by Value
4.3.3 The US Pharmacological Onychomycosis Market by Route of Administration
4.3.4 The US Topical Onychomycosis Market by Value
4.3.5 The US Oral Onychomycosis Market by Value
4.4 The US Onychomycosis Market: Drug Availability Analysis
4.4.1 The US Pharmacological Onychomycosis Market by Drug Availability
4.5 The US Onychomycosis Market: Prescription Drugs Analysis
4.5.1 The US Prescription Onychomycosis Drugs Market by Value
4.5.2 The US Prescription Onychomycosis Market Value by Product (Jubila and Kerydin)
4.6 The US Onychomycosis Market: OTC Drugs Analysis
4.6.1 The US OTC Onychomycosis Drugs Market by Value

5. Competitive Landscape
5.1 Competition in Onychomycosis Prescription Market: An Overview
5.2 Financial Comparison of Major Players of the US Onychomycosis Market

6. Company Profiles
6.1 Bausch Health Companies (Formerly Valeant Pharmaceuticals)
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategy
6.2 Pfizer Inc.
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategy
6.3 Johnson & Johnson
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategy
6.4 Novartis AG
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategy

List of Figures
Figure 1: Types of Onychomycosis
Figure 2: Treatment for Onychomycosis
Figure 3: Global Nail Care Market by Value; 2017-2020 (US$ Billion)
Figure 4: Global Nail Care Market by Value; 2021-2025 (US$ Billion)
Figure 5: Global Nail Care Market by Segments; 2020 (Percentage, %)
Figure 6: Global Onychomycosis Market by Value; 2017-2020 (US$ Billion)
Figure 7: Global Onychomycosis Market by Value; 2021-2025 (US$ Billion)
Figure 8: Global Onychomycosis Market by Segments; 2020 (Percentage, %)
Figure 9: Global Kerydin Drugs Market by Value; 2017-2020 (US$ Million)
Figure 10: Global Kerydin Drugs Market by Value; 2021-2025 (US$ Million)
Figure 11: Global Jublia Drugs Market by Value; 2017-2020 (US$ Million)
Figure 12: Global Jublia Drugs Market by Value; 2021-2025 (US$ Million)
Figure 13: Phase II Drugs (Onychomycosis) Pipeline Forecast; 2021-2026 (US$ Million)
Figure 14: Phase III Drugs (Onychomycosis) Pipeline Forecast; 2018-2026 (US$ Million)
Figure 15: Global Onychomycosis Market by Countries; 2020 (Percentage, %)
Figure 16: The US Nail Care Market by Value; 2017–2020 (US$ Billion)
Figure 17: The US Nail Care Market by Value; 2021–2025 (US$ Billion)
Figure 18: The US Nail Care Market by Segments; 2020 (Percentage, %)
Figure 19: The US Onychomycosis Market by Value; 2017–2020 (US$ Billion)
Figure 20: The US Onychomycosis Market by Value; 2021–2025 (US$ Billion)
Figure 21: The US Onychomycosis Market by Type of Treatment; 2020 (Percentage, %)
Figure 22: The US Pharmacological Onychomycosis Market by Value; 2017-2020 (US$ Billion)
Figure 23: The US Pharmacological Onychomycosis Market by Value; 2021-2025 (US$ Billion)
Figure 24: The US Pharmacological Onychomycosis Market by Route of Administration; 2020 (Percentage, %)
Figure 25: The US Topical Onychomycosis Market by Value; 2017-2020 (US$ Billion)
Figure 26: The US Topical Onychomycosis Market by Value; 2021-2025 (US$ Billion)
Figure 27: The US Oral Onychomycosis Market by Value; 2017-2020 (US$ Billion)
Figure 28: The US Oral Onychomycosis Market by Value; 2021-2025 (US$ Billion)
Figure 29: The US Pharmacological Onychomycosis Market by Drug Availability; 2020 (Percentage, %)
Figure 30: The US Prescription Onychomycosis Drugs Market by Value; 2017-2020 (US$ Billion)
Figure 31: The US Prescription Onychomycosis Drugs Market by Value; 2021-2025 (US$ Billion)
Figure 32: The US Prescription Onychomycosis Market Value by Product; 2020 (Percentage, %)
Figure 33: The US OTC Onychomycosis Drugs Market by Value; 2017-2020 (US$ Million)
Figure 34: The US OTC Onychomycosis Drugs Market by Value; 2021-2025 (US$ Million)
Figure 35: Bausch Health Companies; 2016-2020 (US$ Billion)
Figure 36: Bausch Revenue by Segments; 2020 (Percentage, %)
Figure 37: Bausch Revenue by Region; 2020 (Percentage, %)
Figure 38: Pfizer Inc. Revenue; 2016-2020 (US$ Billion)
Figure 39: Pfizer Inc. Revenue by Region; 2020 (Percentage, %)
Figure 40: Johnson & Johnson Total Sales; 2016-2020 (US$ Billion)
Figure 41: Johnson & Johnson Total Sales by Segments; 2020 (Percentage, %)
Figure 42: Johnson & Johnson Total Sales by Region; 2020 (Percentage, %)
Figure 43: Novartis AG Business Segments
Figure 44: Novartis AG Net Sales; 2016-2020 (US$ Billion)
Figure 45: Novartis AG Net Sales by Segment; 2020 (Percentage, %)
Figure 46: Novartis AG Net Sales by Region; 2020 (Percentage, %)
Table 1: Treatments Available for Onychomycosis
Table 2: Financial Comparison of Major Players of the US Onychomycosis Market

Samples

Executive Summary

There are five types of Onychomycosis: Distal Subungual Onychomycosis, White superficial onychomycosis, Proximal subungual onychomycosis, Endonyx onychomycosis and Candidal onychomycosis. Two types of treatments are available of onychomycosis: Oral Treatment and Topical Treatment. Oral treatment includes: Terbinafine, Itraconazole, etc. and topical treatment includes Kerydin, Jublia, etc. Nonpharmacologic approaches are also there, which includes the following: Laser treatment, Photodynamic therapy, etc.

The US onychomycosis market is forecasted to grow at a healthy growth rate during the forecast period (2021-2025). The US onychomycosis market is supported by various growth drivers, such as rising per capita healthcare expenditure, increasing diabetic patients, ageing population, introduction of new drugs, etc. Yet, the market faces certain challenges, such as, reimbursements, low awareness, side effects, etc.

Companies Mentioned

• Bausch Health Companies (Formerly Valeant Pharmaceuticals)
• Johnson and Johnson
• Novartis AG
• Pfizer, Inc.